Tell us about your partnerships
We currently have over 14 formalized partners. We have many partners from the user side including the Ministry of Health of El Salvador, the Desmond Tutu HIV Foundation, and the London School of Hygiene and Tropical Medicine. We are also beginning a partnership with Partners in Health. Their expertise in and existing network of community health workers throughout Africa would be help greatly. We recently met with PATH, who has expertise in global technology deployment. We have been pursuing partnerships with corporations and other investors.
Are you currently targeting other specific populations, locations, or markets for your innovation? If so, where and why?
We are actively pursuing markets for LRIs and vaccine delivery. With LRIs, we are pursuing clinical trial partners. With vaccine studies, we are pursuing funding. In addition to those, we are reminded of other current markets for COPD and TB which exist but for which we have yet not penetrated. COPD in central Asia, including India, is perhaps more a more acute situation than even Africa. TB in rural China is also a major issue, and we have begun conversations with some partners there. Our penetration into the Americas begins with El Salvador, but will include Central and South America.
What type of operating environment and internal organizational factors make your innovation successful?
We are relying on existing infrastructure in the early growth phase. Institutional infrastructure at our University partners and Ministries are being offered for this tremendous life-saving idea. We have found incredible institutional commitment among our partners. We think our chief organizational advantage lies in our value proposition to our partners. We are working to fund the medical devices that will help our end users so that it is free to them. We are going to take carbon out of the sky and give our carbon-producing partners a way to continue their operations and still fight climate change. Because we have such straightforward value propositions, our collaborative model, which depends on other organizations, is feasible.
Please elaborate on any needs or offers you have mentioned above and/or suggest categories of support that aren't specified within the list
Our main need is funding and assistance with developing details about our business model. Additional experience with regulatory and manufacturing will also help us accelerate our goals. We have an innovative team with international research and engineering experience and are happy to collaborate with others.